Maze Therapeutics Appoints Two Directors, Restructures Board Classes

What Happened

• Maze Therapeutics (MAZE) filed an 8‑K on August 13, 2026 announcing that the Board appointed Paula A. Johnson, M.D., M.P.H. as a Class III director (term to expire at the 2028 annual meeting) and Sophie Kornowski, Pharm.D. as a Class I director (term to expire at the 2029 annual meeting). Each appointment is effective August 13, 2026.
• The Board assigned Dr. Johnson to the nominating and corporate governance committee and Dr. Kornowski to the audit and compensation committees. The company issued a press release about the appointments (Exhibit 99.1).
• To rebalance board classes per the charter and Delaware law, Nancy C. Andrews was moved from Class III to Class II (term expiring 2027) and Hervé Hoppenot was moved from Class II to Class III (term expiring 2028), effective August 13, 2026.

Key Details

• Appointment date: August 13, 2026. Press release furnished as Exhibit 99.1.
• Director pay: each new non‑employee director will receive a pro rata portion of the $40,000 annual cash retainer for 2026 plus applicable committee retainers.
• Equity grant: each new director received an option to buy 36,000 shares, vesting 1/36th each month subject to continued service.
• Background highlights: Dr. Johnson is President of Wellesley College with extensive academic medicine/public health leadership; Dr. Kornowski has senior executive and investment experience in global biopharma.

Why It Matters

• Governance: These appointments and the class reassignments rebalance the staggered board structure and add experienced medical and industry expertise to Maze’s board—potentially strengthening oversight on clinical, public‑health and business development matters.
• Financial impact: Compensation grants are standard for non‑employee directors (pro rata cash retainer and options); the equity awards are modest and vest monthly, implying gradual dilution rather than a large immediate impact.
• No related‑party issues: The filing states there are no family relationships or reportable related‑party transactions involving the new directors.